1. Using a stepwise, interdisciplinary approach, an algorithm was developed to improve the rates of safety alarms set on ventilators ...
1. All-cause mortality at 28 days was significantly higher in the usual care group compared to the casirivimab and imdevimab ...
1. All-cause mortality at 28 days was significantly higher in the usual care group compared to the casirivimab and imdevimab ...
1. Patients hospitalized with COVID-19 receiving at least one dose of molnupiravir did not show reduced mortality compared to patients ...
1. Milrinone was shown not to be significantly different than dobutamine for the treatment of cardiogenic shock. 2. In-hospital deaths ...
1. Among patients hospitalized with severe COVID-19 and hyperinflammation, treatment using the anti-interleukin-1β antibody canakinumab, compared with placebo, did not ...
1. This phase III drug trial showed that dexamethasone does not significantly reduce risk of adverse events and death following ...
1. Patients with prior episodes of critical illness requiring ICU admission were found to have an elevated risk of suicide ...
1. Treatment with dexmedetomidine was shown not to differ from propofol treatment in adult patients with sepsis who were under ...
1. In this single center quality improvement study, the use of any volume-targeted ventilation in premature infants increased by 16%, and ...
